Mylan Rejects $40-Billion Bid from Teva | Fox Business
Drugmaker Teva makes $40B bid for rival Mylan
Mylan Should Try Teva On for Size - WSJ
Teva Pharmaceutical Industries Ltd. ends its hostile bid for Mylan NV - Pittsburgh Business Times
Teva Makes Hostile Bid To Acquire Mylan
Mylan Rejects Teva Takeover Bid As Too Low | Mint
Mylan surprises analysts, Teva with long-delayed Copaxone approvals | Fierce Pharma
Big blow for Teva as FDA approves Mylan's generic Copaxone - Globes
Teva Pharmaceutical Industries' quest to acquire Mylan NV could wind up in a Dutch court - Pittsburgh Business Times
Teva's Generic EpiPen Will Cost As Much As Mylan's Generic | Time
Teva responds to Mylan backlash with planned launch of generic EpiPen | Healthcare IT News
Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid | Reuters
Mylan sues generic rival Teva over 'sophisticated scheme' to block Copaxone copycats | Fierce Pharma
Teva or Mylan: Who Has the More Promising Revenue Trajectory?
Teva makes $40 billion offer for Mylan
How Mylan tried to keep Teva from selling a generic EpiPen
Mylan Raises Offer for Perrigo Again and Is Rejected Again - The New York Times
Generic EpiPen Cleared By FDA As Teva Challenges Mylan
Teva drops bid for Mylan, buys Allergan's generics unit | Pittsburgh Post-Gazette
Mylan NDEA contamination prompts Teva recall in US
Teva wins FDA nod for its generic of Mylan's EpiPen after 2-year delay | Fierce Pharma
US lawmakers push Mylan, Teva over drug pricing probe - www.israelhayom.com
Teva offers to buy Mylan in $40 billion deal | The Times of Israel
Israel-Based Teva Pharmaceutical Industries Smacks Down With Mylan With $40B Bid - YouTube
Teva offers to buy rival Mylan for $40 billion | Fortune
